Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.